A Phase 2, Double‐Blind, Placebo‐Controlled Trial to Investigate Potential Drug‐Drug Interactions Between Cannabidiol and Clobazam

We investigated the effects of cannabidiol (CBD; 21‐day maintenance dose) on the pharmacokinetics (PK) of clobazam (CLB) and monitored the safety of CBD (or placebo) plus CLB in 20 patients with uncontrolled epilepsy on stable doses of CLB. Blood samples collected until 24 hours postdose were evalua...

Descripción completa

Detalles Bibliográficos
Autores principales: VanLandingham, Kevan E., Crockett, Julie, Taylor, Lesley, Morrison, Gilmour
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
NON COVID ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540496/
https://www.ncbi.nlm.nih.gov/pubmed/32652616
http://dx.doi.org/10.1002/jcph.1634

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7540496/
https://www.ncbi.nlm.nih.gov/pubmed/32652616
http://dx.doi.org/10.1002/jcph.1634

Ejemplares similares